health-related quality of life with zanubrutinib versus ibrutinib for patients with r/r cll
Published 1 year ago • 509 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
1:34
the mutational profile in patients with cll treated with acalabrutinib or ibrutinib
-
1:13
monitoring patients with cll on ibrutinib-based therapies
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
1:12
patients with cll on continuous ibrutinib have a life expectancy comparable to healthy individuals
-
3:16
aspen: zanubrutinib vs ibrutinib in waldenström's macroglobulinemia
-
2:29
real-world comparison of ttnt with ibrutinib or acalabrutinib in cll
-
1:09
how can we manage cll without worsening patients’ quality of life?
-
4:27
leigh's story: living well with chronic lymphocytic leukaemia (cll)
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
6:43
key highlights in cll: clinical trial updates & the role of combination therapies and novel btkis
-
0:38
pain management for patients with scd and thalassemia in lebanon
-
2:09
real-world incidence of ibrutinib-related cardiotoxicity in cll: insights from the lls registry
-
3:41
the cll treatment infection model: identifying patients with cll at high risk of infections
-
3:30
treatment options for young, newly diagnosed & low-risk patients with cll
-
0:49
venice ii trial: health-related qol in patients with cll treated with venetoclax
-
0:56
fixed-duration treatment strategies for frontline and relapsed cll
-
1:00
insights into the future of the cll treatment landscape
-
2:10
a study investigating the incidence of treatment-emergent autoimmune cytopenias in cll
-
1:40
challenges in monitoring for cardiotoxicity when treating patients with cll
-
1:44
the impact of acalabrutinib treatment by line of therapy in patients with cll
-
4:05
comparing continuous and fixed duration therapy in cll
-
3:28
the importance of the life cycle of cll cells and how it can inform treatment